HealthMedical Research
mRNA Cancer Vaccine Slashes Melanoma Recurrence by 49%
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
—4 min read
Tag
#Melanoma
3 articles
Health & ScienceTechnology
mRNA Vaccine Cuts Melanoma Recurrence Risk by 49% in Trial
A personalized mRNA cancer vaccine from Moderna and Merck reduced melanoma recurrence risk by 49% over five years, marking a major advance.
—4 min read
HealthMedical Research
mRNA Vaccine Shows Lasting Protection Against Melanoma
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.
—4 min read